Jane Street Group LLC Sells 364,657 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Jane Street Group LLC decreased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 90.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,251 shares of the biopharmaceutical company's stock after selling 364,657 shares during the period. Jane Street Group LLC's holdings in Catalyst Pharmaceuticals were worth $777,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC bought a new stake in Catalyst Pharmaceuticals in the fourth quarter worth $27,000. Farther Finance Advisors LLC boosted its holdings in Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after acquiring an additional 1,495 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Catalyst Pharmaceuticals during the 4th quarter worth approximately $65,000. KBC Group NV grew its position in Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company's stock worth $98,000 after acquiring an additional 1,542 shares during the last quarter. Finally, Quarry LP purchased a new position in Catalyst Pharmaceuticals in the 4th quarter worth approximately $104,000. Institutional investors own 79.22% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX traded up $0.35 on Tuesday, reaching $24.84. The stock had a trading volume of 937,199 shares, compared to its average volume of 1,105,487. Catalyst Pharmaceuticals, Inc. has a 12-month low of $14.75 and a 12-month high of $26.16. The firm has a market capitalization of $3.03 billion, a price-to-earnings ratio of 21.05, a price-to-earnings-growth ratio of 3.31 and a beta of 0.70. The company has a 50-day simple moving average of $23.57 and a 200-day simple moving average of $22.56.

Insiders Place Their Bets

In other Catalyst Pharmaceuticals news, insider Gary Ingenito sold 44,904 shares of Catalyst Pharmaceuticals stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $22.09, for a total transaction of $991,929.36. Following the completion of the transaction, the insider now owns 68,873 shares in the company, valued at approximately $1,521,404.57. The trade was a 39.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Brian Elsbernd sold 62,975 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The shares were sold at an average price of $22.98, for a total transaction of $1,447,165.50. Following the sale, the insider now directly owns 188,564 shares of the company's stock, valued at $4,333,200.72. This trade represents a 25.04% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 351,879 shares of company stock worth $8,214,815. 10.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on CPRX. Stephens reaffirmed an "overweight" rating and issued a $33.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. Robert W. Baird boosted their price objective on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the company an "outperform" rating in a research report on Monday, March 3rd. Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. HC Wainwright restated a "buy" rating and set a $35.00 price target on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Finally, Baird R W upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Monday, February 3rd. Seven research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $32.29.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.